PHARMA NEWS, MULT...
Follow
Find
82.9K views | +43 today

#Pharma Ramps Up Ads & Lobbying to Fend Off Rx Pricing Regulation

From www.wsj.com

The pharmaceutical industry, under fire this election season for rising drug prices, is ramping up a new advertising campaign designed to improve its reputation with lawmakers as it lobbies against any effort to rein in prescription costs. 


The sector’s largest trade group, the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it intends to spend several million dollars this year, and 10% more than in 2015, on digital, radio and print ads that emphasize the industry’s role in developing new drugs and advancing medical science.
 

Many of the ads are running on social-media sites like Facebook, LinkedIn and Twitter,because PhRMA wants to target federal and state lawmakers, policy analysts and other political “influencers,” said Robert Zirkelbach, senior vice president of communications at PhRMA, which represents nearly three dozen of the largest drugmakers, including Pfizer Inc. and Amgen Inc.


Websites like Facebook promise to deliver ads to specific audiences based on characteristics including their location, occupation and keyword search history. 


The campaign is primarily directed at policy makers in Washington, but ads will also run in some select states that have yet to be determined, Mr. Zirkelbach said.

Pharma Guy's curator insight, February 8, 7:21 AM

Are pharma PACs & people still giving money to Bush? http://sco.lt/6K6grZ 

Debunking common myths about healthcare consumerism | McKinsey on Healthcare

From healthcare.mckinsey.com

Until recently, consumerism in the U.S. healthcare industry has moved slowly. However, several converging forces are likely to change the situation soon and result in a more dynamic market.

No comment yet.

The Digital Transformation in Pharma

From www.linkedin.com

Marianne Kryhlmand, a brand manager from Lundbeck , will be presenting at ”The digital transformation in Pharma” conference, April 13-14 in Copenhagen. Prior to the conference she have been asked by the organizers to shed some light on our beliefs at Lundbeck regarding the digital transformation in the pharmaceutical industry.

No comment yet.

Des blockbusters de l'industrie pharmaceutique en ligne de mire

From www.lesechos.fr

La radiation envisagée de la « liste en sus » de produits comme l'Avastin de Roche ou l'Alimta de Lilly inquiète. Le...
No comment yet.

Les Laboratoires Pierre Fabre annoncent le lancement de « Pierre Fabre Fund for Innovation »

From www.lasemainedecastres.fr

Les Laboratoires Pierre Fabre, 2ème laboratoire pharmaceutique indépendant français, annoncent le lancement du Pierre Fabre Fund for Innovation, une initiative originale d’open innovation.
No comment yet.

Twitter Is Good for the Promotion of Drugs of a Certain Sort

From www.ipwatchdog.com

The pharmaceutical world has been flocking to Twitter, just like the rest of the universe, often in an attempt to draw attention to new scientific discoveries aiding in the treatment of disease or to connect with others in their field.


However, Twitter’s popularity has not only benefited the legitimate side of the pharmaceutical industry. A study released in December, supported by both the Global Health Policy Institute and the Alliance for Safe Online Pharmaciesfound an empirical link between all Twitter content and content aimed at the illicit drug sales. A survey of two week’s worth of posts shared on Twitter, involving the analysis of more than two million tweets, turned up 45,000 tweets which encouraged drug abuse. The survey found that more than three-quarters of tweets both pertaining to the non-medical use of prescription medications and including a hyperlink to a sales affiliate related to the anti-anxiety drug Valium.



No comment yet.

Social media in the pharmaceutical industry

From pharmaguapa.com

This week I had the immense pleasure of attending SMI’s Social Media in the Pharmaceutical Industry conference.  As always I enjoyed the event, catching up with many of the #hcsmeu twitterati and hearing insights from the industry and patients.

The event started for me on Tuesday as I led a workshop looking at how pharma can successfully engage using social media (you can find my presentation here).  With a small group we discussed some of the common issues that we still face in this space, for example internal barriers, lack of adequate process and poor understanding of this channel.

Most of these issues have been around for many years now and it does sadden me that they still need to be addressed in so many pharmacos.  On the other hand it is great to be able to have a much richer and deeper set of case studies to use in the battle in bringing some of these barriers down.  “We can’t because of regulations” clearly no longer cuts it – regulations have been clearly shown to not be a barrier.  Another element that appears to still be an issue, and which saddens me greatly, is the view that social media does not need to be approached strategically.  Whilst I am a huge advocate of pharma companies getting involved in social media I do not condone or recommend doing social media for the sake of it.  There does need to be a clear strategy and plan – otherwise you are just taking pot shots in the dark – and frankly doing any form of business, marketing or communication without a strategy is just plain old bad business.

I was very  happy however to see on Day 1 of the conference Stine Sorensen from Lundbeck discussing strategy, and not only its importance but the importance of having a regularly updated strategy (in this case she updates it every 6 months).  I was also very happy to hear Stine mention that she now has the review & approval time for social media content down to 25minutes.  I have had quite a few clients tell me that 24 hour approval times are unrealisitic so it is great to be able to counter this with the fact that quite a few companies now have process in place for near-to-live response.  Not being able to respond very rapidly due to inappropriate review & approval process should no longer be a barrier (and mini self plug – I can help you work this out).  In fact Stine supported everything I always say – there is no longer any room for excuses around not doing social media.  Those days are gone and, as her slides so beautifully shows, excuses are useless!

Another great presentation was given by my friend Jackie Cuyvers, who recently left ZS to set up her own social listening company.  Jackie is an extremely experienced social listener and she now specialises in doing global / local listening.  Besides flagging the importance of asking the right, business questions, she talked us through some of the implications of social listening, in particular some of the linguistic and cultural elements that we tend not to think about.  She mentioned how even in the same language there are big differences across countries and groups in use of terminology.  In the UK for example “pants” means something quite different from “pants” in the US (underwear versus trousers) or the term “good crack” which means different things in the US and Ireland.  She also made the point that just translating content directly often totally overlooks cultural nuances and local idiosyncrasies. In English for example we use the term “kick the bucket” but in Slovenia the translation of this term would be “whispering with crabs”.  This has potentially huge implications on companies running social listening research, especially if they are dependend on pure technology or English language researchers.  I also loved the fact that Jackie got an image of a dog into the conference – tres social!

Jackie’s summary of the 3 steps to social listening

One emphasis that came through throughout the conference though was the importance of patients and the incredible role they play, and the huge value that social media brings to them.  The event was actually kicked off by three fabulous ladies, Birgit Bauer, Silja Chouquet and Marlo Donato Love who shared some great insights from a patient’s perspective and mentioned one of my favourite quotes “patients are the most underutilised resource in the pharmaceutical industry”.  They talked about the importance of getting patients involved and the role they can play in working with pharma.  Silja then also went on to talk about patients participating and “attending” medical conference virtually via social media.  In fact she raised the point that whilst doctor’s are the main participants online at conferences patients are also increasingly getting involved as they search for more information on their conditions.  She also made some great points about the futility of pharma’s current approach to using promoted tweets and how this is potentially going to be a big issue resulting in dilution of high value content on Twitter.

Perhaps a highlight for me though was Trevor Fossey  who talked us through the impact of digital on patients and the NHS.  I was nearly crying as he told us that he has access to his NHS medical record online, and that of this wife for whom he cares, and that as of 1st April every NHS patient has a right to access their medical record online.  OMG!  As a UK patient, with a chronic autoimmune disease, not having access to my medical records has been a big issue.  I have been to numerous doctors, privately in the UK and abroad, and have never been able to show them my NHS blood results as I did not have access to them.  Of course the fact that I now live abroad and don’t have a GP means in all liklihood I still won’t be able to access them but the realisation of what this means for other UK patients, including my elderly parents, was profound.  Trevor mentioned some fantastic points about how impactful empowered patients really are – and how much money they save the NHS.  I can tell you I was certainly not the only person in the room blown away but Trevor’s presentation – despite being a room full of digitally savvy people none of us where aware of our right to access our medical records online.  Trevor found himself a whole group of advocates at the event (I for one have alreay shared to news to all my UK friends and family).

There were so many other great presentations, such as Letizia Affinito who showed us some great non-pharma case studies, and Pinal Patel from BMS who showed us how they are using social media in clinical trials – and more importantly how they are listening to patients and adapting their process in response to patient feedback.  An awesome point was made that often once a trial is over patients are just left alone – but really we should be thanking them and sharing the results with them (something BMS plans to do now thanks to feedback).  Charlotte Roth from Actelion also gave the Corporate POV around social media, bringing an additional dimension to the conference, while Liz Skrbkova shared perspectives around multi-channel engagement and online influencers. I also have to add that IMHO Liz was one of the best dressed ladies at the event :)

Last but not least was the pleasure of meeting all these amazing people and having some great discussions, including over wine and dinner.  Dinner also gave me the opportunity to catch up with a couple more of the #hcsmeu and the next day I was able to sample some of the most amazing cocktails at the Alchemist in the evening.  Afterall what would a social media conference be if it didn’t include the “social” bit!


No comment yet.

Almirall's Eduardo Sanchiz and Alfonso Ugarte with their view on patient centricity to pharma - eyeforpharma Barcelona 2016

From www.eyeforpharma.com

In these exclusive videos eyeforpharma's Paul SImms spoke with Eduardo Sanchiz and Alfonso Ugarte, resp CEO and Senior Director of Global Business Units of Almirall, on the changing pharma landscape, patient value and rewriting the business plan.


rob halkes's curator insight, February 6, 10:11 AM

Inspiring to see the leadership of Almirall speaking about their personal drives to lead their company to patient centricity.

PatientView's curator insight, February 8, 4:01 AM

@almirall  is featured in our new corporate rep report in March 2016  43 patient groups commenti on the company

#Pharma is Not Ready to be Patient Centric, Says This Patient Blogger

From www.linkedin.com

With all due respect, you are not automatically a “patient-centric” company just because you added that term to your marketing materials and hired someone with an eponymous title who travels the country with a spectacular LinkedIn profile on fact-finding missions to buy nonprofit CEO’s lunch to data mine their insights.


And don’t get me started on regulatory. We in the Patient Advocacy sector are not naive to The Physician Payments Sunshine Act. (It just rolls off the tongue, doesn’t it?) This onomatopoeic law is killing all of us. It stifles innovation (with a lower case “i”), presents innumerable encumbrances to actually getting anything done and ties up any possibility for success in a sea of red tape negotiations.


My point is that that a re-imagining of patient-centricity needs to occur STAT. Otherwise no one wins.


PAOs are at fault too. We can’t just take your money and not expect to produce ROI. And yet, there are a few nonprofits for whom ROI is in their DNA. They operate using program management and evidence-based patient outcome reporting. Pharmas that choose to meaningfully engage with these groups benefit from a measurable competitive advantage by viewing us as business partners, rather than charities looking for a handout.

Pharma Guy's curator insight, February 6, 10:42 AM

I guess this patient's points are (1) transparency of payments to physicians somehow stifles "innovation," and (2) payments to Patient Advocacy Organizations (PAOs) should be fees for service!

Big data dans la santé avec la big pharma

From www.informatiquenews.fr

Les grandes sociétés de l’IT et de l’internet s’intéressent de très près aux applications du big data dans le domaine de la santé : IBM a signé un partenar
No comment yet.

Digital : le PDG d’Accor crée un Comité exécutif des moins de 35 ans

From www.larevuedudigital.com

A l’heure du digital, il faut absolument écouter les moins de 35 ans. C’est le leitmotiv de Sébastien Bazin, PDG du groupe …
Romain DEFOY's curator insight, February 5, 3:08 AM

 “Les 12 garçons et filles du shadow Comex, le Comex de l’ombre, vont avoir accès à 100% de toutes les informations privilégiées, confidentielles, auxquelles j’ai accès que ce soit sur l’actionnariat, sur les marges, sur les achats, la distribution, tout, 100% de l’agenda qui est le mien, tous les mois,” annonce Sébastien Bazin, PDG du groupe hôtelier Accor.

Quel modèle d'entreprise pour lutter contre l'uberisation ? #pharma #hcsmeufr

From www.fredcavazza.net

La semaine dernière, nous avons encore eu droit à une belle démonstration de violence des chauffeurs de taxi. Une action très spectaculaire, mais bien dérisoire, car s’ils peuvent éventuellement faire pression sur le gouvernement pour... Lire la suite
No comment yet.

Big Pharma spending big to push patients to take their meds

From www.statnews.com

Drug companies around the globe are spending big to push patients to take their pills.

The pharma industry loses tens of billions in worldwide sales each year when patients don’t fill, or refill, their prescriptions.

So drug makers from London to Tokyo to Cambridge, Mass., are pouring money into programs aimed at cajoling — or nagging — patients to take every last pill their doctors prescribe. The companies are investing in smart pills that will send alerts when they haven’t been swallowed at the prescribed time. They’re subsidizing gift cards to thank patients who remember to refill. They’re paying patients to go on talk circuits to tout the virtues of taking medication properly.

No comment yet.

Pharma adoption of social media: A prescription for physician engagement

From www.slideshare.net

DELOITTE : Pharma adoption of social media: A prescription for physician engagement
No comment yet.

3 Reasons Why #Pharma Marketers Are Failing At Social Media #hcsmeufr #hcsmeues

From xtalks.com

While social media has undoubtedly become an integral part of many people’s daily lives, the pharmaceutical industry is lagging when it comes to harnessing the potential power of Twitter and Instagram. Pharma marketers have historically been much more comfortable with the one-sided conversation of a direct-to-consumer (DTC) ad, but as the industry moves more and more towards patient-centricity, it is becoming necessary for drugmakers to increase engagement with their stakeholders.
No comment yet.

Digital Analytics 101 for Healthcare Marketers: SEM and Paid Search

From www.mdconnectinc.com

Across the globe, digital tools are transforming how marketers approach their audiences. But despite this overwhelming consensus, the healthcare industry is often slow to adopt new marketing techniques. As a result, many healthcare professionals are still asking a question that most of us presumed answered a long time ago: “Why digital?”

The reality is that this change in healthcare, as in all industries, is a necessity — the internet is now the primary way that consumers engage with healthcare companies. As John Weston, CMO at Mayo Clinic, explained in a recent AdAge article, “The consumer-to-patient journey is largely a digital journey at their moment of need.” Indeed, at least 72% of Americans look online for health information each year, according to Pew Internet, and that includes medical professionals.

“If I were diagnosed with something tomorrow, one of the first things I would do is go online,” Weston added.

Given how wide this market has become, healthcare marketers must adapt their strategies to better capture and hold the attention of online audiences. But any digital marketing strategy is only as strong as its foundation, which begs the question: where’s the best place to start?

No comment yet.

How pharma can stay competitive in the digital world

From www.mmm-online.com

As drugmakers seek new ways to incorporate digital technology into the way they do business, questions persist about whether the culture at traditional pharma companies is willing to change and move toward digitization.

A report from McKinsey & Company compiled interviews with 20 executives from the analytics, pharmaceutical, provider, technology and venture capital sectors. The overall consensus, the authors of the McKinsey report found, is that the industry needs to transform itself to stay competitive.  

“Successful ones will rethink their business and operating models, transform their cultures and capabilities and adopt a new, longer-term mind-set that fosters innovation and bold strategic moves,” wrote the authors of the report.

It's clear that as the adoption of digital initiatives accelerates, pharma companies will need to experiment more and do so more quickly to respond to the changing behaviors of patients, said Olivier Leclerc, a director at McKinsey.

No comment yet.

Ipsen lance le programme NET Patient Accelerator

From buzz-esante.fr

Pour développer de nouveaux services pour les patients atteints de tumeurs neuroendocrines, le laboratoire Ipsen lance le programme NET Patient Accelerator.
No comment yet.

Creating Better Relationships Through Multichannel Marketing

From digitalblog.exlpharma.com

Finding the way to deliver information in a way your customers will gladly accept.
No comment yet.

LEO Pharma launches new innovation lab with $65M in funding for non-pharmaceutical dermatology expansion

From medcitynews.com

LEO Pharma, which has had a primary focus on skin conditions like psoriasis, has launched its new Innovation Lab to further explore treatment options that don't involve medication.
No comment yet.

5 myths physicians believe about patient experience

From www.advisory.com

See why clinician-patient communication, leadership of the care team, and support and empathy for the patient across the unit are the most important factors for success—and how physicians can embrace the role of
No comment yet.

Digital in 2016

From fr.slideshare.net

We Are Social's comprehensive new Digital in 2016 report presents internet, social media, and mobile usage statistics and trends from all over the world. It co…
No comment yet.

» Communication numérique : Merck, Pfizer et AstraZeneca, « grands leaders » de l’étude Indegene 2016

From www.mypharma-editions.com

Indegene, le groupe indien de solutions santé destinées aux entreprises des sciences du vivant, vient de dévoiler les résultats d'une étude mondiale sur les médecins et leurs habitudes numériques. Cette étude met en avant la combinaison de moyens de contact la plus efficace aux États-Unis, au Japon, en Chine et en Inde. Elle identifie également les sociétés que les professionnels de santé eux-mêmes considèrent comme des leaders.
No comment yet.

Doctors on Twitter: Worldwide growth mapped, 2006-2014

From www.youtube.com

Interactive version now at http://bit.ly/GlobalHCPs Video maps growth in doctors, nurses and healthcare professionals using Twitter since its launch in 2006 ...
Danielle Ralic's comment, January 30, 4:38 AM
Explore the data feature does not work? Would be great to be able to understand what kind of data is behind it and explore some new views.